Currently approved only for NJ NGS is indicated for solid tumors in early stage disease where genetic profile from multiple genes informs diagnosis or disease stratification, prognosis, or treatment options. For late stage cancers, NGS can be used to evaluate options for alternative treatments, including targeted therapies or non-responsiveness to a targeted therapy with known resistance mutations. Lincoln Reference Laboratory NGS Mutation Analysis offers: Turnaround time of 7-10 days Broad coverage by most private and public insurance. Specimen Requirement Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and […]

Currently approved only for NJ

NGS is indicated for solid tumors in early stage disease where genetic profile from multiple genes informs diagnosis or disease stratification, prognosis, or treatment options. For late stage cancers, NGS can be used to evaluate options for alternative treatments, including targeted therapies or non-responsiveness to a targeted therapy with known resistance mutations.

Lincoln Reference Laboratory NGS Mutation Analysis offers:

• Turnaround time of 7-10 days
• Broad coverage by most private and public insurance.

Specimen Requirement

1. Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and standard for solid tumor mutation analysis.
2. Specimens are optimally fixed in 10% neutral-buffered formalin, optimal fixation time ranges from 6 to 24 hours.
3. Presence of tumor cells in the sample must be assessed by a pathologist.
4. Ratio of tumor cells to normal cells is crucial for adequate mutation testing and should be provide by the pathologist.
5. One H&E slide and 3-5 unstained slides (6-8microns ideal) are required for mutation testing.